Royal Bank of Canada
CADL icon

Royal Bank of Canada’s Candel Therapeutics CADL Stock Holding History

Royal Bank of Canada’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Sell
600
-1,245
-67% -$6.78K ﹤0.01% 6566
2025
Q4 		$10K Buy
1,845
+851
+86% +$4.58K ﹤0.01% 6404
2025
Q3 		$5K Sell
994
-13,180
-93% -$76.2K ﹤0.01% 6684
2025
Q2 		$71K Buy
14,174
+11,489
+428% +$59.1K ﹤0.01% 5763
2025
Q1 		$15K Buy
2,685
+2,154
+406% +$17.6K ﹤0.01% 6008
2024
Q4 		$5K Sell
531
-2,302
-81% -$13.6K ﹤0.01% 6522
2024
Q3 		$19K Buy
2,833
+569
+25% +$3.54K ﹤0.01% 6119
2024
Q2 		$15K Buy
2,264
+2,195
+3,181% +$16.5K ﹤0.01% 6176
2024
Q1 		$0 Buy
69
+39
+130% +$58 ﹤0.01% 7045
2023
Q4 		$0 Sell
30
-276
-90% -$268 ﹤0.01% 7142
2023
Q3 		$0 Buy
306
+143
+88% +$165 ﹤0.01% 7107
2023
Q2 		$0 Buy
+163
New +$241 ﹤0.01% 7274

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's CADL Position: Q1 2026 in Review

Royal Bank of Canada reduced its Candel Therapeutics (CADL) stake by 67% in Q1 2026, selling an estimated $6.78K and leaving 600 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #6566.

Royal Bank of Canada first reported a position in CADL in Q2 2023 and has held it in 12 quarters since. The position peaked at $71K in Q2 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Royal Bank of Canada held 600 shares of Candel Therapeutics worth $3K as of Q1 2026.
  • Royal Bank of Canada sold 1,245 Candel Therapeutics shares in Q1 2026, an estimated $6.78K.
  • Candel Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6566 holding.
  • Royal Bank of Canada first reported a position in Candel Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Royal Bank of Canada's Candel Therapeutics position peaked at $71K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.